BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38684435)

  • 1. [Pathogenesis of myelodysplastic syndromes by excessive mitochondrial fragmentation].
    Hayashi Y
    Rinsho Ketsueki; 2024; 65(4):249-254. PubMed ID: 38684435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes.
    Aoyagi Y; Hayashi Y; Harada Y; Choi K; Matsunuma N; Sadato D; Maemoto Y; Ito A; Yanagi S; Starczynowski DT; Harada H
    Cancer Discov; 2022 Jan; 12(1):250-269. PubMed ID: 34462274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
    Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
    J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of HIF1A in the development of myelodysplastic syndromes].
    Hayashi Y
    Rinsho Ketsueki; 2019; 60(7):818-823. PubMed ID: 31391372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
    An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
    Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
    Matos A; Magalhães SMM; Rauh MJ
    Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulation of microRNAs in myelodysplastic syndrome.
    Rhyasen GW; Starczynowski DT
    Leukemia; 2012 Jan; 26(1):13-22. PubMed ID: 21852786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA dysregulation in the myelodysplastic syndromes.
    Chung SS; Park CY
    Microrna; 2014; 2(3):174-86. PubMed ID: 25069441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
    Lindberg EH
    Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immune signaling in the myelodysplastic syndromes.
    Starczynowski DT; Karsan A
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome.
    Craven SE; French D; Ye W; de Sauvage F; Rosenthal A
    Blood; 2005 May; 105(9):3528-34. PubMed ID: 15650063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome.
    Bereshchenko O; Lo Re O; Nikulenkov F; Flamini S; Kotaskova J; Mazza T; Le Pannérer MM; Buschbeck M; Giallongo C; Palumbo G; Li Volti G; Pazienza V; Cervinek L; Riccardi C; Krejci L; Pospisilova S; Stewart AF; Vinciguerra M
    Clin Epigenetics; 2019 Aug; 11(1):121. PubMed ID: 31439048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
    Wei Y; Zheng H; Bao N; Jiang S; Bueso-Ramos CE; Khoury J; Class C; Lu Y; Lin K; Yang H; Ganan-Gomez I; Starczynowski DT; Do KA; Colla S; Garcia-Manero G
    Blood Adv; 2018 Oct; 2(19):2491-2504. PubMed ID: 30275007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes.
    Maurya N; Mohanty P; Panchal P; Shanmukhaiah C; Vundinti BR
    Mol Biol Rep; 2023 Jan; 50(1):235-244. PubMed ID: 36322239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.